viernes, 13 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Target Just Posted Its First Sales Growth in 5 Quarters. So Why Did the Stock Drop Anyway?

View original at finance.yahoo.com
Target Just Posted Its First Sales Growth in 5 Quarters. So Why Did the Stock Drop Anyway? Shares of big-box retailer Target(NYSE: TGT) slid about 4% after the company reported its fiscal first quarter of 2026 (the period ended May 2, 2026) earlier this week…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Business momentum in Q1 FY2026 was broad-based: all six core merchandise categories grew, store traffic rose 4.4%, digital comparable sales jumped 8.9%, and higher-margin non-merchandise revenue grew nearly 25%.

    60% confidence

  • Target will make more changes to what it sells and how it sells it in 2026 than has been seen in a decade.

    60% confidence

  • Comparable sales rose 5.6% in Q1 FY2026, Target's first positive comparable-sales reading in five quarters and its strongest comparable-sales gain in approximately four years.

    60% confidence

  • Excluding the ~$0.97/share one-time legal settlement gain from Q1 FY2025, adjusted prior-year EPS was approximately $1.30, making Q1 FY2026 EPS of $1.71 represent approximately 32% year-over-year growth.

    60% confidence

Data points we hold from this source

Target Corporation · net income781 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Target Just Posted Its First Sales Growth in 5 Quarters. So Why Did the Stock Drop Anyway? — Source | Via News | es.VIA.NEWS